The scale-X nexo bioreactor from Univercells Technologies by Donaldson helps reduce process development timelines, driving down costs for researchers and biopharma companies alike. The new bioreactor offers a 0.5 m² growth surface, designed for efficient cell culture process development across multiple modalities. As the smallest member of the scale-X family, the tiny but mighty scale-X nexo bioreactor ensures consistent cell distribution and high cell density, laying the groundwork for efficient, scalable biomanufacturing. Its direct scalability to the scale-X carbo (10-30 m²) and nitro bioreactor (200-600 m²) makes it a powerful tool for companies aiming to move swiftly from lab to commercial production while minimizing costs.
The scale-X nexo bioreactor is designed to reduce media and reagent consumption, thanks to its low-volume, low-surface-area approach. This efficiency not only minimizes resource needs use but also reduces seed train efforts—resulting in a streamlined, cost-effective bioprocess offering up to a 60% reduction in cost per run compared with other entry-level fixed-bed bioreactors. Its versatile, ready-to-use manifolds enable rapid setup and precise screening for a variety of process conditions and applications, such as cell and gene therapies and vaccines, among others.